SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4oya'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1V55_C_CHDC3271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE III CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.91A	1v55C-4oyaA: undetectable 1v55J-4oyaA: undetectable	1v55C-4oyaA: 19.62 1v55J-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2DYS_P_CHDP310_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.02A	2dysP-4oyaA: undetectable 2dysW-4oyaA: undetectable	2dysP-4oyaA: 19.62 2dysW-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EIJ_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.92A	2eijC-4oyaA: undetectable 2eijJ-4oyaA: undetectable	2eijC-4oyaA: 19.62 2eijJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EIK_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.95A	2eikC-4oyaA: undetectable 2eikJ-4oyaA: undetectable	2eikC-4oyaA: 19.62 2eikJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EIM_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.97A	2eimC-4oyaA: undetectable 2eimJ-4oyaA: undetectable	2eimC-4oyaA: 19.62 2eimJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EIN_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.93A	2einC-4oyaA: undetectable 2einJ-4oyaA: undetectable	2einC-4oyaA: 19.62 2einJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EIN_P_CHDP1271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.91A	2einP-4oyaA: undetectable 2einW-4oyaA: undetectable	2einP-4oyaA: 19.62 2einW-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HW2_A_RFPA1200_1 (RIFAMPIN ADP-RIBOSYL TRANSFERASE)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	PHE A 348 GLY A 434 THR A 293 SER A 388 GLY A 464	None	0.92A	2hw2A-4oyaA: undetectable	2hw2A-4oyaA: 16.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2I2Z_A_SALA1100_1 (SERUM ALBUMIN)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 5	LEU A 325 ILE A 321 ILE A 369 ALA A 366	GOL A 502 (-4.3A) None None None	0.73A	2i2zA-4oyaA: undetectable	2i2zA-4oyaA: 22.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2JC9_A_ADNA1497_1 (CYTOSOLIC PURINE 5'-NUCLEOTIDASE)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	ASP A 99 THR A 52 ILE A 79 ASN A 76	1VE A 501 (-2.5A) None None None	1.14A	2jc9A-4oyaA: undetectable	2jc9A-4oyaA: 21.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2PRG_A_BRLA1_1 (PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	GLY A 330 GLN A 331 HIS A 164 TYR A 318 HIS A 162	None GOL A 502 (-3.7A) None None GOL A 502 (-4.1A)	1.19A	2prgA-4oyaA: undetectable	2prgA-4oyaA: 18.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2RLC_A_CHDA332_0 (CHOLOYLGLYCINE HYDROLASE)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	ALA A 182 ASN A 185 ILE A 204 ILE A 202 ASN A 216	None	1.05A	2rlcA-4oyaA: undetectable	2rlcA-4oyaA: 19.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZW9_B_SAMB801_1 (LEUCINE CARBOXYL METHYLTRANSFERASE 2)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 8	ILE A 407 ASN A 412 ARG A 176 SER A 49	None None 1VE A 501 (-3.2A) None	1.04A	2zw9B-4oyaA: undetectable	2zw9B-4oyaA: 21.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ZXW_P_CHDP1271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.93A	2zxwP-4oyaA: undetectable 2zxwW-4oyaA: undetectable	2zxwP-4oyaA: 19.62 2zxwW-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ABL_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 5	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.01A	3ablC-4oyaA: undetectable 3ablJ-4oyaA: undetectable	3ablC-4oyaA: 19.62 3ablJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ABL_P_CHDP1271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.98A	3ablP-4oyaA: undetectable 3ablW-4oyaA: undetectable	3ablP-4oyaA: 19.62 3ablW-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AG1_C_CHDC271_0 (CYTOCHROME C OXIDASE POLYPEPTIDE 7A1 CYTOCHROME C OXIDASE SUBUNIT 3)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	0.98A	3ag1C-4oyaA: undetectable 3ag1J-4oyaA: undetectable	3ag1C-4oyaA: 19.62 3ag1J-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SP9_A_IL2A901_1 (PEROXISOME PROLIFERATOR-ACTIVAT ED RECEPTOR DELTA)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	CYH A 122 ILE A 115 LEU A 147 VAL A 187 TYR A 240	None	1.19A	3sp9A-4oyaA: undetectable	3sp9A-4oyaA: 19.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4EQ4_A_SALA601_1 (4-SUBSTITUTED BENZOATES-GLUTAMATE LIGASE GH3.12)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	LEU A 75 THR A 55 THR A 405 GLY A 98	None	0.94A	4eq4A-4oyaA: undetectable	4eq4A-4oyaA: 22.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4S0V_A_SUVA2001_2 (HUMAN OREXIN RECEPTOR TYPE 2 FUSION PROTEIN TO P. ABYSII GLYCOGEN SYNTHASE)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 5	ILE A 277 PRO A 12 TYR A 26 VAL A 25	None	1.36A	4s0vA-4oyaA: undetectable	4s0vA-4oyaA: 21.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4USW_A_ACTA1469_0 (ADENYLATE CYCLASE TYPE 10)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 4	LYS A 95 HIS A 164 LYS A 334 VAL A 335	1VE A 501 (-3.8A) None None None	0.42A	4uswA-4oyaA: 59.9	4uswA-4oyaA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4USW_A_ACTA1470_0 (ADENYLATE CYCLASE TYPE 10)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 6	LYS A 95 LEU A 102 LEU A 166 VAL A 167 PHE A 336	1VE A 501 (-3.8A) 1VE A 501 (-3.6A) 1VE A 501 (-3.9A) 1VE A 501 (-3.7A) 1VE A 501 (-3.9A)	0.57A	4uswA-4oyaA: 59.9	4uswA-4oyaA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5B1B_C_CHDC306_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.01A	5b1bC-4oyaA: undetectable 5b1bJ-4oyaA: undetectable	5b1bC-4oyaA: 19.62 5b1bJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5JI0_D_BRLD501_1 (PEROXISOME PROLIFERATOR-ACTIVAT ED RECEPTOR GAMMA)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	GLY A 330 GLN A 331 HIS A 164 TYR A 318 HIS A 162	None GOL A 502 (-3.7A) None None GOL A 502 (-4.1A)	1.16A	5ji0D-4oyaA: undetectable	5ji0D-4oyaA: 18.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5JW1_B_CELB602_2 (PROSTAGLANDIN G/H SYNTHASE 2)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	VAL A 167 ARG A 33 ILE A 314 PHE A 157	1VE A 501 (-3.7A) None None None	1.05A	5jw1B-4oyaA: undetectable	5jw1B-4oyaA: 20.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5KBW_B_RBFB201_1 (RIBOFLAVIN TRANSPORTER RIBU)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	LEU A 345 LYS A 334 GLY A 98 ALA A 414 VAL A 391	None	1.28A	5kbwB-4oyaA: undetectable	5kbwB-4oyaA: 16.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5KIR_B_RCXB601_2 (PROSTAGLANDIN G/H SYNTHASE 2)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 4	LEU A 166 ARG A 33 ILE A 314 PHE A 157	1VE A 501 (-3.9A) None None None	1.09A	5kirB-4oyaA: undetectable	5kirB-4oyaA: 22.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_A_Z80A401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 11	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	1.01A	5lg3A-4oyaA: undetectable	5lg3A-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_E_Z80E401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.97A	5lg3E-4oyaA: undetectable	5lg3E-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_F_Z80F401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 10	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.98A	5lg3F-4oyaA: undetectable	5lg3F-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_G_Z80G401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 10	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.99A	5lg3G-4oyaA: undetectable	5lg3G-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_H_Z80H401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 10	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.97A	5lg3H-4oyaA: 0.1	5lg3H-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_I_Z80I401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 9	ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.90A	5lg3I-4oyaA: undetectable	5lg3I-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LG3_J_Z80J401_1 (GAMMA-AMINOBUTYRIC-A CID RECEPTOR SUBUNIT BETA-1)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	ILE A 79 ILE A 48 VAL A 396 THR A 405 ILE A 407	None	0.97A	5lg3J-4oyaA: undetectable	5lg3J-4oyaA: 19.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OF1_B_SALB301_1 (SPORE COAT-ASSOCIATED PROTEIN N)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 5	ALA A 97 VAL A 406 PHE A 336 ILE A 294	1VE A 501 (-3.1A) None 1VE A 501 (-3.9A) None	0.91A	5of1B-4oyaA: undetectable	5of1B-4oyaA: 11.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5XDH_A_DAHA60_1 (PUTATIVE CYTOCHROME C)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	HIS A 19 ASN A 333 LEU A 274 GLN A 331	None None None GOL A 502 (-3.7A)	1.44A	5xdhA-4oyaA: undetectable 5xdhC-4oyaA: undetectable	5xdhA-4oyaA: 12.86 5xdhC-4oyaA: 12.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z84_P_CHDP305_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.08A	5z84P-4oyaA: undetectable 5z84W-4oyaA: undetectable	5z84P-4oyaA: 19.62 5z84W-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z85_P_CHDP307_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.11A	5z85P-4oyaA: undetectable 5z85W-4oyaA: undetectable	5z85P-4oyaA: 19.62 5z85W-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z86_C_CHDC306_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.01A	5z86C-4oyaA: undetectable 5z86J-4oyaA: undetectable	5z86C-4oyaA: 19.62 5z86J-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Z86_P_CHDP307_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.04A	5z86P-4oyaA: undetectable 5z86W-4oyaA: undetectable	5z86P-4oyaA: 19.62 5z86W-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZCP_C_CHDC306_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.07A	5zcpC-4oyaA: undetectable 5zcpJ-4oyaA: undetectable	5zcpC-4oyaA: 19.62 5zcpJ-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZCP_P_CHDP306_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.10A	5zcpP-4oyaA: undetectable 5zcpW-4oyaA: undetectable	5zcpP-4oyaA: 19.62 5zcpW-4oyaA: 8.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6AJI_A_AY6A1001_0 (DRUG EXPORTERS OF THE RND SUPERFAMILY-LIKE PROTEIN,ENDOLYSIN)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	5 / 12	ILE A 145 ILE A 82 VAL A 86 LEU A 147 VAL A 175	None	1.16A	6ajiA-4oyaA: 5.6	6ajiA-4oyaA: 19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6CK2_C_IPHC101_0 (INSULIN A CHAIN INSULIN B CHAIN)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 4	ILE A 384 LEU A 299 HIS A 320 ALA A 317	None	0.86A	6ck2C-4oyaA: undetectable 6ck2D-4oyaA: undetectable	6ck2C-4oyaA: 4.15 6ck2D-4oyaA: 5.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6D9K_F_ACTF802_0 (UNCHARACTERIZED PROTEIN)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	3 / 3	TYR A 26 ALA A 17 LEU A 255	None CME A 253 ( 4.4A) None	0.75A	6d9kF-4oyaA: undetectable	6d9kF-4oyaA: 22.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6J20_A_GBQA1201_1 (SUBSTANCE-P RECEPTOR,ENDOLYSIN)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 7	ILE A 82 GLU A 131 HIS A 127 VAL A 143	None	1.08A	6j20A-4oyaA: undetectable	6j20A-4oyaA: 21.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6NMP_C_CHDC307_0 (CYTOCHROME C OXIDASE SUBUNIT 3 CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL)	4oya	ADENYLATE CYCLASE TYPE 10 (Homo sapiens)	4 / 6	GLN A 375 PHE A 372 LEU A 299 PHE A 301	None	1.03A	6nmpC-4oyaA: undetectable 6nmpJ-4oyaA: undetectable	6nmpC-4oyaA: 19.62 6nmpJ-4oyaA: 8.46

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1V55_C_CHDC3271_0","CYTOCHROME C OXIDASE POLYPEPTIDE III;CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.91A","1v55C-4oyaA:undetectable;1v55J-4oyaA:undetectable","1v55C-4oyaA:19.62;1v55J-4oyaA:8.46"],["2DYS_P_CHDP310_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.02A","2dysP-4oyaA:undetectable;2dysW-4oyaA:undetectable","2dysP-4oyaA:19.62;2dysW-4oyaA:8.46"],["2EIJ_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.92A","2eijC-4oyaA:undetectable;2eijJ-4oyaA:undetectable","2eijC-4oyaA:19.62;2eijJ-4oyaA:8.46"],["2EIK_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.95A","2eikC-4oyaA:undetectable;2eikJ-4oyaA:undetectable","2eikC-4oyaA:19.62;2eikJ-4oyaA:8.46"],["2EIM_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.97A","2eimC-4oyaA:undetectable;2eimJ-4oyaA:undetectable","2eimC-4oyaA:19.62;2eimJ-4oyaA:8.46"],["2EIN_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.93A","2einC-4oyaA:undetectable;2einJ-4oyaA:undetectable","2einC-4oyaA:19.62;2einJ-4oyaA:8.46"],["2EIN_P_CHDP1271_0","CYTOCHROME C OXIDASE POLYPEPTIDE VIIA-HEART;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.91A","2einP-4oyaA:undetectable;2einW-4oyaA:undetectable","2einP-4oyaA:19.62;2einW-4oyaA:8.46"],["2HW2_A_RFPA1200_1","RIFAMPIN ADP-RIBOSYL TRANSFERASE","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"PHE A 348;GLY A 434;THR A 293;SER A 388;GLY A 464","None","0.92A","2hw2A-4oyaA:undetectable","2hw2A-4oyaA:16.16"],["2I2Z_A_SALA1100_1","SERUM ALBUMIN","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"LEU A 325;ILE A 321;ILE A 369;ALA A 366","GOL A 502 (-4.3A);None;None;None","0.73A","2i2zA-4oyaA:undetectable","2i2zA-4oyaA:22.76"],["2JC9_A_ADNA1497_1","CYTOSOLIC PURINE 5'-NUCLEOTIDASE","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ASP A  99;THR A  52;ILE A  79;ASN A  76","1VE A 501 (-2.5A);None;None;None","1.14A","2jc9A-4oyaA:undetectable","2jc9A-4oyaA:21.30"],["2PRG_A_BRLA1_1","PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"GLY A 330;GLN A 331;HIS A 164;TYR A 318;HIS A 162","None;GOL A 502 (-3.7A);None;None;GOL A 502 (-4.1A)","1.19A","2prgA-4oyaA:undetectable","2prgA-4oyaA:18.97"],["2RLC_A_CHDA332_0","CHOLOYLGLYCINE HYDROLASE","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ALA A 182;ASN A 185;ILE A 204;ILE A 202;ASN A 216","None","1.05A","2rlcA-4oyaA:undetectable","2rlcA-4oyaA:19.75"],["2ZW9_B_SAMB801_1","LEUCINE CARBOXYL METHYLTRANSFERASE 2","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ILE A 407;ASN A 412;ARG A 176;SER A  49","None;None;1VE A 501 (-3.2A);None","1.04A","2zw9B-4oyaA:undetectable","2zw9B-4oyaA:21.58"],["2ZXW_P_CHDP1271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.93A","2zxwP-4oyaA:undetectable;2zxwW-4oyaA:undetectable","2zxwP-4oyaA:19.62;2zxwW-4oyaA:8.46"],["3ABL_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.01A","3ablC-4oyaA:undetectable;3ablJ-4oyaA:undetectable","3ablC-4oyaA:19.62;3ablJ-4oyaA:8.46"],["3ABL_P_CHDP1271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.98A","3ablP-4oyaA:undetectable;3ablW-4oyaA:undetectable","3ablP-4oyaA:19.62;3ablW-4oyaA:8.46"],["3AG1_C_CHDC271_0","CYTOCHROME C OXIDASE POLYPEPTIDE 7A1;CYTOCHROME C OXIDASE SUBUNIT 3","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","0.98A","3ag1C-4oyaA:undetectable;3ag1J-4oyaA:undetectable","3ag1C-4oyaA:19.62;3ag1J-4oyaA:8.46"],["3SP9_A_IL2A901_1","PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"CYH A 122;ILE A 115;LEU A 147;VAL A 187;TYR A 240","None","1.19A","3sp9A-4oyaA:undetectable","3sp9A-4oyaA:19.29"],["4EQ4_A_SALA601_1","4-SUBSTITUTED BENZOATES-GLUTAMATE LIGASE GH3.12","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"LEU A  75;THR A  55;THR A 405;GLY A  98","None","0.94A","4eq4A-4oyaA:undetectable","4eq4A-4oyaA:22.58"],["4S0V_A_SUVA2001_2","HUMAN OREXIN RECEPTOR TYPE 2 FUSION PROTEIN TO P. ABYSII GLYCOGEN SYNTHASE","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ILE A 277;PRO A  12;TYR A  26;VAL A  25","None","1.36A","4s0vA-4oyaA:undetectable","4s0vA-4oyaA:21.22"],["4USW_A_ACTA1469_0","ADENYLATE CYCLASE TYPE 10","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"LYS A  95;HIS A 164;LYS A 334;VAL A 335","1VE A 501 (-3.8A);None;None;None","0.42A","4uswA-4oyaA:59.9","4uswA-4oyaA:100.00"],["4USW_A_ACTA1470_0","ADENYLATE CYCLASE TYPE 10","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"LYS A  95;LEU A 102;LEU A 166;VAL A 167;PHE A 336","1VE A 501 (-3.8A);1VE A 501 (-3.6A);1VE A 501 (-3.9A);1VE A 501 (-3.7A);1VE A 501 (-3.9A)","0.57A","4uswA-4oyaA:59.9","4uswA-4oyaA:100.00"],["5B1B_C_CHDC306_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.01A","5b1bC-4oyaA:undetectable;5b1bJ-4oyaA:undetectable","5b1bC-4oyaA:19.62;5b1bJ-4oyaA:8.46"],["5JI0_D_BRLD501_1","PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"GLY A 330;GLN A 331;HIS A 164;TYR A 318;HIS A 162","None;GOL A 502 (-3.7A);None;None;GOL A 502 (-4.1A)","1.16A","5ji0D-4oyaA:undetectable","5ji0D-4oyaA:18.90"],["5JW1_B_CELB602_2","PROSTAGLANDIN G\/H SYNTHASE 2","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"VAL A 167;ARG A  33;ILE A 314;PHE A 157","1VE A 501 (-3.7A);None;None;None","1.05A","5jw1B-4oyaA:undetectable","5jw1B-4oyaA:20.65"],["5KBW_B_RBFB201_1","RIBOFLAVIN TRANSPORTER RIBU","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"LEU A 345;LYS A 334;GLY A  98;ALA A 414;VAL A 391","None","1.28A","5kbwB-4oyaA:undetectable","5kbwB-4oyaA:16.03"],["5KIR_B_RCXB601_2","PROSTAGLANDIN G\/H SYNTHASE 2","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"LEU A 166;ARG A  33;ILE A 314;PHE A 157","1VE A 501 (-3.9A);None;None;None","1.09A","5kirB-4oyaA:undetectable","5kirB-4oyaA:22.26"],["5LG3_A_Z80A401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","1.01A","5lg3A-4oyaA:undetectable","5lg3A-4oyaA:19.92"],["5LG3_E_Z80E401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.97A","5lg3E-4oyaA:undetectable","5lg3E-4oyaA:19.92"],["5LG3_F_Z80F401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.98A","5lg3F-4oyaA:undetectable","5lg3F-4oyaA:19.92"],["5LG3_G_Z80G401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.99A","5lg3G-4oyaA:undetectable","5lg3G-4oyaA:19.92"],["5LG3_H_Z80H401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.97A","5lg3H-4oyaA:0.1","5lg3H-4oyaA:19.92"],["5LG3_I_Z80I401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.90A","5lg3I-4oyaA:undetectable","5lg3I-4oyaA:19.92"],["5LG3_J_Z80J401_1","GAMMA-AMINOBUTYRIC-ACID RECEPTOR SUBUNIT BETA-1","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A  79;ILE A  48;VAL A 396;THR A 405;ILE A 407","None","0.97A","5lg3J-4oyaA:undetectable","5lg3J-4oyaA:19.92"],["5OF1_B_SALB301_1","SPORE COAT-ASSOCIATED PROTEIN N","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ALA A  97;VAL A 406;PHE A 336;ILE A 294","1VE A 501 (-3.1A);None;1VE A 501 (-3.9A);None","0.91A","5of1B-4oyaA:undetectable","5of1B-4oyaA:11.06"],["5XDH_A_DAHA60_1","PUTATIVE CYTOCHROME C;PUTATIVE CYTOCHROME C","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"HIS A  19;ASN A 333;LEU A 274;GLN A 331","None;None;None;GOL A 502 (-3.7A)","1.44A","5xdhA-4oyaA:undetectable;5xdhC-4oyaA:undetectable","5xdhA-4oyaA:12.86;5xdhC-4oyaA:12.86"],["5Z84_P_CHDP305_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.08A","5z84P-4oyaA:undetectable;5z84W-4oyaA:undetectable","5z84P-4oyaA:19.62;5z84W-4oyaA:8.46"],["5Z85_P_CHDP307_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.11A","5z85P-4oyaA:undetectable;5z85W-4oyaA:undetectable","5z85P-4oyaA:19.62;5z85W-4oyaA:8.46"],["5Z86_C_CHDC306_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.01A","5z86C-4oyaA:undetectable;5z86J-4oyaA:undetectable","5z86C-4oyaA:19.62;5z86J-4oyaA:8.46"],["5Z86_P_CHDP307_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.04A","5z86P-4oyaA:undetectable;5z86W-4oyaA:undetectable","5z86P-4oyaA:19.62;5z86W-4oyaA:8.46"],["5ZCP_C_CHDC306_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.07A","5zcpC-4oyaA:undetectable;5zcpJ-4oyaA:undetectable","5zcpC-4oyaA:19.62;5zcpJ-4oyaA:8.46"],["5ZCP_P_CHDP306_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.10A","5zcpP-4oyaA:undetectable;5zcpW-4oyaA:undetectable","5zcpP-4oyaA:19.62;5zcpW-4oyaA:8.46"],["6AJI_A_AY6A1001_0","DRUG EXPORTERS OF THE RND SUPERFAMILY-LIKE PROTEIN,ENDOLYSIN","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",5,"ILE A 145;ILE A  82;VAL A  86;LEU A 147;VAL A 175","None","1.16A","6ajiA-4oyaA:5.6","6ajiA-4oyaA:19.44"],["6CK2_C_IPHC101_0","INSULIN A CHAIN;INSULIN B CHAIN","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ILE A 384;LEU A 299;HIS A 320;ALA A 317","None","0.86A","6ck2C-4oyaA:undetectable;6ck2D-4oyaA:undetectable","6ck2C-4oyaA:4.15;6ck2D-4oyaA:5.82"],["6D9K_F_ACTF802_0","UNCHARACTERIZED PROTEIN","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",3,"TYR A  26;ALA A  17;LEU A 255","None;CME A 253 ( 4.4A);None","0.75A","6d9kF-4oyaA:undetectable","6d9kF-4oyaA:22.14"],["6J20_A_GBQA1201_1","SUBSTANCE-P RECEPTOR,ENDOLYSIN","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"ILE A  82;GLU A 131;HIS A 127;VAL A 143","None","1.08A","6j20A-4oyaA:undetectable","6j20A-4oyaA:21.63"],["6NMP_C_CHDC307_0","CYTOCHROME C OXIDASE SUBUNIT 3;CYTOCHROME C OXIDASE SUBUNIT 7A1, MITOCHONDRIAL","4oya","ADENYLATE CYCLASE TYPE 10","Homo sapiens",4,"GLN A 375;PHE A 372;LEU A 299;PHE A 301","None","1.03A","6nmpC-4oyaA:undetectable;6nmpJ-4oyaA:undetectable","6nmpC-4oyaA:19.62;6nmpJ-4oyaA:8.46"]]